首页> 中文期刊> 《吉林中医药》 >中药汤剂辅助治疗气滞血瘀型心绞痛

中药汤剂辅助治疗气滞血瘀型心绞痛

         

摘要

Objective To explore the clinical effects of traditional Chinese medicine decoction in the treatment of angina pectoris with qi stagnation and blood stasis. Methods120 patients with angina pectoris of qi stagnancy and blood stasis syndrome were randomly divided into observation group and control group, 60 patients in each group. They were treated with Xuefu Zhuyu decoction combined with routine treatment of western medicine and simple western medicine treatment for 4 weeks. To observe and compare the clinical efficacy of the two groups after treatment, angina pectoris duration, attack frequency, nitroglycerin, TCM syndrome integral, integral and laboratory indexes BNP angina, high-sensitivity C-reactive protein and Fg levels were observed of the two groups before and after the treatment. Results After treatment, the total efficiency of 83.3% in observation groupwas significantly higher than that of the control group of 71.6% (P<0.05); Duration of angina attack, attack times, nitroglycerin dosage, TCM syndrome integral, angina pectoris degree score was significantly lower in observation group after treatment than control group (P<0.05); BNP, high-sensitivity c-reactive protein and Fg levels in observation group after treatment were significantly lower than control group (P<0.05). Conclusion Xuefu Zhuyu decoction to treat angina pectoris with qi stagnation and blood stasis can get better curative effect than routine treatment, significantly improve the angina symptoms and degree, reduce the laboratory indexes related to the development risk of coronary heart diseaseand good security.%目的 探索中药汤剂血府逐瘀汤辅助治疗气滞血瘀型心绞痛的临床疗效.方法 120例气滞血瘀型心绞痛患者随机分为观察组与对照组各60例,分别给予血府逐瘀汤联合西医常规治疗与单纯西医常规治疗,疗程为4周.观察并比较2组治疗后的临床疗效,2组治疗前后的心绞痛持续时间、发作次数、硝酸甘油服用量,中医证候积分、心绞痛程度积分与实验室指标BNP、高敏C反应蛋白、Fg水平.结果 治疗后观察组的总有效率83.3%显著高于对照组71.6%(P<0.05);治疗后观察组的心绞痛发作持续时间、发作次数、硝酸甘油服用量、中医证候积分、心绞痛程度积分显著低于对照组(P<0.05);治疗后观察组的BNP、高敏C反应蛋白、Fg水平均显著低于对照组(P<0.05).结论 中药汤剂血府逐瘀汤辅助治疗气滞血瘀型心绞痛可获得较单纯常规治疗更好的疗效,明显改善了心绞痛症状与程度,降低了与冠心病发生发展风险有关的实验室指标,且安全性较好.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号